The transition to medication adoption in publicly funded substance use disorder treatment programs: Organizational structure, culture, and resources

Journal of Studies on Alcohol and Drugs

Volumn 75, Issue 3, 2014, Pages 476-485

  Knudsen, Hannah K ^a   Roman, Paul M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COHORT ANALYSIS; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; ECONOMICS; FOLLOW UP; HEALTH CARE POLICY; HUMAN; LONGITUDINAL STUDY; MEDICAID; ORGANIZATION AND MANAGEMENT; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MEDICAID; PATIENT PROTECTION AND AFFORDABLE CARE ACT; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84901652398     PISSN: 19371888     EISSN: 19384114     Source Type: Journal    
DOI: 10.15288/jsad.2014.75.476     Document Type: Article

References (67)

1. Abraham, A. J., Knudsen, H. K., Rieckmann, T., & Roman, P. M. (2013). Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. Journal of Studies on Alcohol and Drugs, 74, 258-265.
2. Abraham, A. J., Knudsen, H. K., & Roman, P. M. (2011). A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: Patterns of sustainability and discontinuation. Journal of Studies on Alcohol and Drugs, 72, 669-677.
3. Abraham, A. J., Knudsen, H. K., Rothrauff, T. C., & Roman, P. M. (2010). The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The infl uence of research network participation. Journal of Substance Abuse Treatment, 38, 275-283.
4. Addiction Technology Transfer Center Network Technology Transfer Workgroup. (2011). Research to practice in addiction treatment: Key terms and a fi eld-driven model of technology transfer. Journal of Substance Abuse Treatment, 41, 169-178.
5. Alexander, J. A., Wheeler, J. R., Nahra, T. A., & Lemak, C. H. (1998). Managed care and technical effi ciency in outpatient substance abuse treatment units. Journal of Behavioral Health Services & Research, 25, 377-396.
6. Allison, P. D. (2002). Missing data. Thousand Oaks, CA: Sage.
7. Barnard, J., & Rubin, D. B. (1999). Small-sample degrees of freedom with multiple imputation. Biometrika, 86, 948-955.
8. Buck, J. A. (2011). The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs, 30, 1402-1410.
9. Capoccia, V. A., Grazier, K. L., Toal, C., Ford, J. H., II, & Gustafson, D. H. (2012). Massachusetts's experience suggests coverage alone is insuffi cient to increase addiction disorders treatment. Health Affairs, 31, 1000-1008.
10. Cartwright, W. S., & Solano, P. L. (2003). The economics of public health: Financing drug abuse treatment services. Health Policy, 66, 247-260.
11. Ching, A. T., & Ishihara, M. (2012). Measuring the informative and persuasive roles of detailing on prescribing decisions. Management Science, 58, 1374-1387.
12. Chriqui, J. F., Terry-McElrath, Y., McBride, D. C., & Eidson, S. S. (2008). State policies matter: The case of outpatient drug treatment program practices. Journal of Substance Abuse Treatment, 35, 13-21.
13. Ducharme, L. J., Knudsen, H. K., & Roman, P. M. (2006). Trends in the adoption of medications for alcohol dependence. Journal of Clinical Pharmacology, 26, Supplement 1, S13-S19.
14. Ducharme, L. J., Knudsen, H. K., Roman, P. M., & Johnson, J. A. (2007). Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment, 32, 321-329.
15. Fiellin, D. A. (2007). The first three years of buprenorphine in the United States: Experience to date and future directions. Journal of Addiction Medicine, 1, 62-67.
16. Fischer, M. A., Keough, M. E., Baril, J. L., Saccoccio, L., Mazor, K. M., Ladd, E., Gurwitz, J. H. (2009). Prescribers and pharmaceutical representatives: Why are we still meeting? Journal of General Internal Medicine, 24, 795-801.
17. Friedmann, P. D., D'Aunno, T. A., Jin, L., & Alexander, J. A. (2000). Medical and psychosocial services in drug abuse treatment: Do stronger linkages promote client utilization? Health Services Research, 35, 443-465.
18. Friedmann, P. D., Jiang, L., & Alexander, J. A. (2010). Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. Journal of Behavioral Health Services & Research, 37, 322-337.
19. Friedmann, P. D., Zhang, Z., Hendrickson, J., Stein, M. D., & Gerstein, D. R. (2003). Effect of primary medical care on addiction and medical severity in substance abuse treatment programs. Journal of General Internal Medicine, 18, 1-8.
20. Fuller, B. E., Rieckmann, T., McCarty, D., Smith, K. W., & Levine, H. (2005). Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment, 28, 273-280.
21. Garfield, R. L., Lave, J. R., & Donohue, J. M. (2010). Health reform and the scope of benefi ts for mental health and substance use disorder services. Psychiatric Services, 61, 1081-1086.
22. Heinrich, C. J., & Fournier, E. (2004). Dimensions of publicness and performance in substance abuse treatment organizations. Journal of Policy Analysis and Management, 23, 49-70.
23. Heinrich, C. J., & Hill, C. J. (2008). Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Services Research, 43, 951-970.
24. Henry J. Kaiser Family Foundation. (2012, June 29). A guide to the Supreme Court's Affordable Care Act Decision. Retrieved from http://www.kff.org/healthreform/upload/8332.pdf
25. Holahan, J., & Headen, I. (2010, May 1). Medicaid coverage and spending in health reform: National and state-by-state results for adults at or below 133% FPL. Retrieved from http://kff.org/health-reform/report/report-and-briefing-on-medicaid-coverage-and/
26. Huddle, T. S. (2008). Drug reps and the academic medical center: A case for management rather than prohibition. Perspectives in Biology and Medicine, 51, 251-260.
27. Katz, D., Caplan, A. L., & Merz, J. F. (2010). All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry giftgiving. American Journal of Bioethics, 10, 11-17.
28. Knudsen, H. K., & Abraham, A. J. (2012). Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders. Psychiatric Services, 63, 19-25.
29. Knudsen, H. K., Abraham, A. J., & Oser, C. B. (2011). Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Evaluation and Program Planning, 34, 375-381.
30. Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2006). Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment, 30, 363-373.
31. Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2007). The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence, 87, 164-174.
32. Knudsen, H. K., Roman, P. M., & Oser, C. B. (2010). Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine, 4, 99-107.
33. Koch, A. L., Arfken, C. L., & Schuster, C. R. (2006). Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug and Alcohol Dependence, 83, 274-278.
34. Kubiak, S. P., Arfken, C. L., & Gibson, E. S. (2009). Departments of corrections as purchasers of community-based treatment: A national study. Journal of Substance Abuse Treatment, 36, 420-427.
35. Litten, R. Z., Egli, M., Heilig, M., Cui, C., Fertig, J. B., Ryan, M. L., Noronha, A. (2012). Medications development to treat alcohol dependence: A vision for the next decade. Addiction Biology, 17, 513-527.
36. Long, J. S. (1997). Regression models for categorical and limited dependent variables. Thousand Oaks, CA: Sage.
37. Long, J. S., & Freese, J. (2006). Regression models for categorical dependent variables using Stata, 2nd edition. College Station, TX: StataCorp.
38. Martino, S., Brigham, G. S., Higgins, C., Gallon, S., Freese, T. E., Albright, L. M., Condon, T. P. (2010). Partnerships and pathways of dissemination: The National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network. Journal of Substance Abuse Treatment, 38, Supplement 1, S31-S43.
39. Mee-Lee, D., Gartner, L., Miller, M. M., Shulman, G. R., & Wilford, B. B. (1996). Patient placement criteria for the treatment of substance-related disorders (2nd ed.). Chevy Chase, MD: American Society of Addiction Medicine.
40. Menard, S. (2008). Panel analysis with logistic regression. In S. Menard (Ed.), Handbook of longitudinal research: Design, measurement, and analysis (pp. 505-522). Burlington, MA: Academic Press.
41. Mizik, N., & Jacobson, R. (2004). Are physicians "easy marks"? Quantifying the effects of detailing and sampling on new prescriptions. Management Science, 50, 1704-1715.
42. Narayanan, S., Desiraju, R., & Chintagunta, P. K. (2004). Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. Journal of Marketing, 68, 90-105.
43. O'Connor, P. G., Nyquist, J. G., & McLellan, A. T. (2011). Integrating addiction medicine into graduate medical education in primary care: The time has come. Annals of Internal Medicine, 154, 56-59.
44. Office of National Drug Control Strategy. (2010). 2010 National Drug Control Strategy. Retrieved from http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/ndcs2010.pdf
45. Oliva, E. M., Maisel, N. C., Gordon, A. J., & Harris, A. H. S. (2011). Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Current Psychiatry Reports, 13, 374-381.
46. Oser, C. B., & Roman, P. M. (2007). Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers. Journal of Studies on Alcohol and Drugs, 68, 852-861.
47. Oser, C. B., & Roman, P. M. (2008). A categorical typology of naltrexoneadopting private substance abuse treatment centers. Journal of Substance Abuse Treatment, 34, 433-442.
48. Polydorou, S., Gunderson, E. W., & Levin, F. R. (2008). Training physicians to treat substance use disorders. Current Psychiatry Reports, 10, 399-404.
49. Rieckmann, T., Kovas, A. E., & Rutkowski, B. A. (2010). Adoption of medications in substance abuse treatment: Priorities and strategies of single state authorities. Journal of Psychoactive Drugs, 42, Supplement 6, 227-238.
50. Rieckmann, T. R., Kovas, A. E., Fussell, H. E., & Stettler, N. M. (2009). Implementation of evidence-based practices for treatment of alcohol and drug disorders: The role of the state authority. Journal of Behavioral Health Services & Research, 36, 407-419.
51. Rodgers, J. H., & Barnett, P. G. (2000). Two separate tracks? A national multivariate analysis of differences between public and private substance abuse treatment programs. American Journal of Drug and Alcohol Abuse, 26, 429-442.
52. Rogers, E. M. (2003). Diffusion of innovations (5th ed.). New York, NY: Free Press.
53. Roman, P. M., Abraham, A. J., & Knudsen, H. K. (2011). Using medicationassisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behaviors, 36, 584-589.
54. Roman, P. M., Ducharme, L. J., & Knudsen, H. K. (2006). Patterns of organization and management in private and public substance abuse treatment programs. Journal of Substance Abuse Treatment, 31, 235-243.
55. Roman, P. M., Johnson, J. A., & Blum, T. C. (2000). The transformation of private alcohol problem treatment. Advances in Medical Sociology, 7, 321-342.
56. Royston, P. (2004). Multiple imputation of missing values. The Stata Journal, 4, 227-241.
57. Royston, P. (2005a). Multiple imputation of missing values: Update. The Stata Journal, 5, 188-201.
58. Royston, P. (2005b). Multiple imputation of missing values: Update office. The Stata Journal, 5, 527-536.
59. Savage, S. A., Abraham, A. J., Knudsen, H. K., Rothrauff, T. C., & Roman, P. M. (2012). Timing of buprenorphine adoption by privately funded substance abuse treatment programs: The role of institutional and resource-based interorganizational linkages. Journal of Substance Abuse Treatment, 42, 16-24.
60. Saxon, A. J., & McCarty, D. (2005). Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology & Therapeutics, 108, 119-128.
61. Thomas, C. P., Garnick, D. W., Horgan, C. M., McCorry, F., Gmyrek, A., Chalk, M., Thatcher, J. (2011). Advancing performance measures for use of medications in substance abuse treatment. Journal of Substance Abuse Treatment, 40, 35-43.
62. Thomas, C. P., Reif, S., Haq, S., Wallack, S. S., Hoyt, A., & Ritter, G. A. (2008). Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatric Services, 59, 909-916.
63. Thomas, C. P., Wallack, S. S., Lee, S., McCarty, D., & Swift, R. (2003). Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment, 24, 1-11.
64. Velasco, E., Espelage, W., Faber, M., Noll, I., Ziegelmann, A., Krause, G., & Eckmanns, T. (2011). A national cross-sectional study on socio-behavioural factors that infl uence physicians' decisions to begin antimicrobial therapy. Infection, 39, 289-297.
65. Warren, K. R., & Hewitt, B. G. (2010). NIAAA: Advancing alcohol research for 40 years. Alcohol Research & Health, 33, 5-17.
66. West, J. C., Kosten, T. R., Wilk, J., Svikis, D., Triffleman, E., Rae, D. S., Regier, D. A. (2004). Challenges in increasing access to buprenorphine treatment for opiate addiction. The American Journal on Addictions, 13, Supplement 1, S8-S16.
67. White, W. (1998). Slaying the dragon: The history of addiction treatment and recovery in America. Bloomington, IL: Chestnut Health Systems.